Where does Wuxi Biologics Ireland Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Wuxi Biologics Ireland Limited ranks #14,391 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Wuxi Biologics Ireland Limited hold?

Wuxi Biologics Ireland Limited holds 21 US utility patents granted between 2021 and 2025, spanning 8 technology areas.

What is Wuxi Biologics Ireland Limited's Innovation Score?

Wuxi Biologics Ireland Limited has an Innovation Score of 50.7 out of 100 (top 12% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Wuxi Biologics Ireland Limited focus on?

Wuxi Biologics Ireland Limited's top technology area is C07K (Peptides) with 20 patents, ranking #490 of 3,615 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is Wuxi Biologics Ireland Limited's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Wuxi Biologics Ireland Limited.

What does claim depth mean for Wuxi Biologics Ireland Limited's patents?

Wuxi Biologics Ireland Limited's patents average 16.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Wuxi Biologics Ireland Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Wuxi Biologics Ireland Limited

USPTO PatentsView assignee record - 21 granted patents across 8 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Wuxi ranks #14,391 of 49,997 tracked US assignees by granted-patent volume, with 21 patents across 8 technology areas.

#14,391
of 49,997 US assignees by volume: Top 12%
by Innovation Score (50.7/100): 16.8
avg claims per patent

USPTO PatentsView assignee plate

Corpus R14391 · Foreign Corporation #14,391 · 21 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-SMALL 21 grants
MID-PACK #14,391/49,997
PHOTO-FINISH Walkme
CPC-NARROW C07K · 8 areas
INNOV-PAR 50.7/100
CLAIMS-RICH 16.8 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2021–2025 · 5y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Walkme Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Wuxi’s 50.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.7 pts (21%) Velocity 20.0 pts (39%) Breadth 10.0 pts (20%) Claim depth 10.1 pts (20%)

Qualcomm Incorporated · highest

85
Wuxi Biologics Ireland · this assignee

51
3D Lighting… · lowest

7

What this shows Wuxi's Innovation Score is 50.7/100 (top 12% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Wuxi?

Each dot is one of Wuxi’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Wuxi’s own 16.8 claims/patent is ABOVE the 12.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Wuxi vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Wuxi's grants concentrate

Wuxi Biologics Ireland Limited is a focused PatentsView assignee: 8 CPC subclasses with 95.2% of grants classified under C07K (Peptides). Peak complete grant year is 2023 (6 grants) versus a trough of 3 in 2021. By volume, Wuxi sits between Westlake Royal Building Products (USA) Inc. and Warwick Mills, Inc..

Wuxi's three-year grant acceleration

Wuxi Biologics Ireland Limited shows 15 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Westlake Royal Bu…

21
William Beaumont…

21
WKI Holding

21
Wonders Holding BV

21
Wuxi Little Swan…

21
WWT North America…

21
Walkme

21
Warwick Mills

21
Wuxi Biologics Ir… ◀

21

What this shows Wuxi holds 21 patents at rank #14,379, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Wuxi

By rank, the assignees closest to #14,379 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Wuxi's primary technology class.

Wuxi's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

51 Top 12% higher than 88% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table

Wuxi Biologics Ireland Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2021	3	14.3%
2022	5	23.8%
2023	6	28.6%
2024	4	19.0%
2025partial year	3	14.3%

Which technologies does Wuxi Biologics Ireland Limited patent most?

C07K - Peptides 20

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 18

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 13

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 10

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 4

Y02A - Technologies FOR Adaptation TO Climate Change 1

C12M - Apparatus FOR Enzymology OR MICROBIOLOGY; Apparatus FOR Culturing Microorganisms FOR Producing Biomass, FOR Growing Cells OR FOR Obtaining Fermentation OR Metabolic Products, i.e. Bioreactors OR Fermenters 1

G01J - Measurement OF Intensity, Velocity, Spectral Content, Polarisation, Phase OR Pulse Characteristics OF Infrared, Visible OR Ultraviolet LIGHT; COLORIMETRY; Radiation Pyrometry 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Wuxi Biologics Ireland Limited's patent record in context - here's where to go next.

Wuxi Biologics Ireland Limited's lead technology class is C07K (Peptides), 95.2% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #14,391 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Wuxi Biologics Ireland Limited against Westlake Royal Building Products (USA) Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 50.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.